about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Look­ing to ce­ment its lead in packed MS mar­ket, Roche's Ocre­vus un­corks new da­ta in ear­ly-stage pa­tients

5 years ago
R&D

Opin­ion: Pfiz­er, BioN­Tech did­n't take US gov­ern­men­t's sup­port to de­vel­op their vac­cine. Let's stop rewrit­ing the ...

5 years ago
Opinion

Abzena picks North Car­oli­na as the home for its 6th man­u­fac­tur­ing site, plans to add 325 jobs in San­ford

5 years ago
Outsourcing
Manufacturing

Roche touts 2-year ef­fi­ca­cy da­ta for SMA ther­a­py Evrys­di; NIH funds new net­work to study flu and virus­es with ...

5 years ago
News Briefing

Bain dou­bles down on Tony Coles’ quest to get a late-stage Parkin­son’s drug through to mar­ket

5 years ago
Financing
R&D

Or­biMed-backed The­seus de­buts with $100M round in hero­ic quest for 'pan-vari­ant' ki­nase in­hibitors

5 years ago
Financing
R&D

AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

5 years ago
R&D
Pharma

AACR21: iTeos busts out ear­ly hu­man da­ta for an­ti-TIG­IT an­ti­body. Is it enough to match up with Roche, Mer­ck?

5 years ago
R&D

AACR21: Zen­tal­is keeps the heat on As­traZeneca with ear­ly WEE1 da­ta show­ing a group of 'ex­cep­tion­al' re­spon­ders

5 years ago
R&D

AACR21 roundup: Ar­cus rolls out PhI da­ta on adeno­sine block­er for CRC; Co­di­ak's en­gi­neered ex­o­some for IL-12 shows ...

5 years ago
R&D

AACR21: Bris­tol My­ers looks to build Op­di­vo's case in ear­ly can­cer with full da­ta in pre-sur­gi­cal NSCLC

5 years ago
R&D

AACR21: As­traZeneca un­veils next-gen PARP in­hibitor, look­ing to fol­low up on suc­cess of first-gen suc­cess sto­ry ...

5 years ago
R&D

AACR21: Sanofi rolls out new da­ta for ear­ly-stage 'non-al­pha' IL-2. Ear­ly feed­back? In­ter­est­ing, but most­ly meh

5 years ago
R&D

Bris­tol My­er­s' Op­di­vo notch­es a dou­ble win against chemo in esophageal can­cer, po­ten­tial­ly set­ting up 1st-line nod

5 years ago
R&D
Pharma

Ver­sant-backed Ven­tus scores $100M round to tur­bocharge its dual-plat­form play at 'drug­ging the un­drug­gable'

5 years ago
Financing

No­var­tis taps DNA dam­age spe­cial­ist Ar­tios in $1.3B dis­cov­ery deal to com­ple­ment grow­ing ra­di­oli­gand port­fo­lio

5 years ago
Deals
Discovery

With fresh in­vestor cash in hand, Volas­tra part­ners with Mi­crosoft to de­vel­op metasta­t­ic can­cer bio­mark­er plat­form

5 years ago
Financing
Deals

Mar­tin Shkre­li push­es back on life­time pub­lic com­pa­ny ban from prison cell in bid to get back to busi­ness

5 years ago
People

Pfiz­er breaks ground on ster­ile in­jecta­bles plant in Michi­gan, plans to add around 450 jobs to the re­gion

5 years ago
Manufacturing

Bris­tol My­ers faces $1B+ tax fight af­ter ac­ci­den­tal dis­clo­sure re­veals al­leged off­shore patents scheme — re­port

5 years ago
Pharma
FDA+

Pi­ra­mal Phar­ma So­lu­tions picks up In­di­an pep­tide API mak­er in push in­to on­col­o­gy, meta­bol­ic con­tract work

5 years ago
Outsourcing
Manufacturing

Move over, Boston and San Fran­cis­co? Seat­tle tops list of fastest grow­ing biotech hubs for job op­por­tu­ni­ties — ...

5 years ago
Pharma

Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

5 years ago
Deals

The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top ...

5 years ago
Pharma
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times